Alkermes commences ALKS 37 phase 1 clinical trial for the treatment of opioid-induced constipation (News-Medical-Net)

Alkermes, Inc. today announced the initiation of a phase 1 clinical study of ALKS 37, an orally active, peripherally-restricted opioid antagonist with potential to block the opioid agonist effects on gastrointestinal motility, commonly referred to as opioid-induced constipation (OIC). The randomized, double-blind, placebo-controlled study will assess the safety, tolerability and pharmacokinetic …
(read here…)

Related items

• World’s first Cs-131 implant for colorectal cancer performed at Weill Cornell Medical Center (News-Medical-Net)
• OncoGenex Pharmaceuticals to pay Isis Pharmaceuticals $10M for license of OGX-011 to Teva Pharmaceutical Industries (News-Medical-Net)
• Bayer’s NEXAVAR approved in over 70 countries for the treatment of liver cancer (News-Medical-Net)
• Medivir AB announces license agreement with Daewoong Pharmaceutical for MIV-210 drug (News-Medical-Net)
• SwissINSO Announces Enhanced Research & Development Capability (Business Wire via Yahoo! Finance)

Tags: Alkermes, alkermes inc, alks, cancer, double blind placebo, gastrointestinal motility, Inc, nano, nanotech, nanotechnology, opioid, safety tolerability, study, Technology, today

This entry was posted on Tuesday, October 27th, 2009 at 7:55 pm and is filed under Technology.